Home RxNorm 2196490 immune globulin subcutaneous (human) - klhw 20 % (4 GM in 20 ML) Injection Drug identity information. FDA.report links public drug records from RxNav, DailyMed, FDA NDC, Drugs@FDA, and related public sources where available. This page is informational only and is not medical, prescribing, or regulatory advice.
RxCUI 2196490
RxNorm name immune globulin subcutaneous (human) - klhw 20 % (4 GM in 20 ML) Injection
Display name immune globulin subcutaneous (human) - klhw 20 % (4 GM in 20 ML) Injection
Full name immune globulin subcutaneous (human) - klhw 20 % (4 GM in 20 ML) Injection
Term type PSN
Status DailyMed mapping
Updated 2026-06-04 23:39:08 Purple Book Biologic Products# BLA, Proprietary name, Proper name table BLA Proprietary name Proper name License type Status Latest source 125683 Xembify immune globulin subcutaneous, human-klhw 351(a) Rx 2026-08-01
RxNav Current And Historical NDCs# RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.
No records found.
UNII Substances# UNII substance links page 1 of 1 · 0 matching rows.
No records found.
DailyMed RxNorm Mappings# unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.
Set ID, RxNorm mappings, Terms table Set ID RxNorm mappings Terms SPL version Label Effective 8c174b11-a061-412e-a3b2-7bf7e1adaace immune globulin subcutaneous (human) - klhw 20 % (4 GM in 20 ML) Injection [PSN] · 20 ML immune globulin subcutaneous (human) - klhw 200 MG/ML Injection [SCD] 2 12 These highlights do not include all the information needed to use XEMBIFY safely and effectively. See full prescribing information for XEMBIFY. XEMBIFY (immune globulin subcutaneous, human – klhw) 20% solution Initial U.S. Approval: 2019 20250317